paclitaxel / Generic mfg. - LARVOL DELTA

BURAN: A phase III study of buparlisib (BUP) plus paclitaxel (PAC) in patients with PD-1(PD-L1)-pretreated recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) (ESMO 2025) - P3 | "Notably, the control arm (PAC alone) demonstrated a longer OS than historically observed in the phase II BERIL-1 trial (median 6.5 mos), potentially contributing to the outcome. Subgroup analyses will be presented at the meeting."

Clinical • Late-breaking abstract • Metastases • P3 data • Head and Neck Cancer • Oncology • Oropharyngeal Cancer • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck

PEMBROLIZUMAB VS PLACEBO PLUS PACLITAXEL ± BEVACIZUMAB FOR PLATINUM-RESISTANT RECURRENT OVARIAN CANCER: RESULTS FROM THE PHASE 3 ENGOTOV65/KEYNOTE-B96 STUDY (IGCS 2025) - P3 | "Efficacy results favored the pembrolizumab arm (Table 1). Subsequent anticancer therapies were used by 52.2% and 60.4% in the pembrolizumab and placebo arms, respectively (Table 2). Grade ≥3 treatment-related adverse events occurred in 67.5% vs 55.3%, respectively."

Clinical • Late-breaking abstract • P3 data • Platinum resistant • Oncology • Ovarian Cancer • Peritoneal Cancer • Solid Tumor • PD-L1

FINAL OVERALL SURVIVAL RESULTS FROM THE GOG281/LOGS STUDY EVALUATING TRAMETINIB VERSUS PHYSICIAN'S CHOICE STANDARD-OF-CARE THERAPY FOR RECURRENT LOW-GRADE SEROUS OVARIAN CANCER (LGSOC) (IGCS 2025) - P2/3 | " This international phase 2/3 trial randomly assigned (1:1) patients with recurrent LGSOC to receive either oral trametinib 2 mg once daily (n=130) or one of five SoC treatment options (n=130): intravenous paclitaxel 80 mg/m² by body surface area on days 1, 8, and 15 of every 28-day cycle; intravenous pegylated liposomal doxorubicin 40–50 mg/m² once every 4 weeks; intravenous topotecan 4 mg/m² on days 1, 8, and 15 of every 28-day cycle; oral letrozole 2·5 mg once daily; or oral tamoxifen 20 mg twice daily. At the time of the final analysis, 29 (22.3%) patients in the trametinib arm and 15 (11.5%) patients in the SoC arm remained alive. The median OS was 36.4 months in the trametinib arm versus 29.8 months in the SoC arm (HR 0.68; 95% CI 0.49-0.94; p=0.018, 1-sided), despite the fact that 72% of patients in the SoC arm crossed over to trametinib following progression. In the 93 SoC patients who crossed over to trametinib the median PFS..."

Clinical • Late-breaking abstract • Oncology • Ovarian Cancer • Ovarian Serous Adenocarcinoma • Solid Tumor

Phase II Study of Opamtistomig (LBL-024), a PD-L1/4-1BB Bispecific Antibody Plus Chemotherapy in First-Line Advanced NSCLC (IASLC-WCLC 2026) - P2 | "The nsqNSCLC cohort received Opamtistomig (15 mg/kg) plus pemetrexed and carboplatin Q3W for 4-6 cycles, followed by maintenance with Opamtistomig plus pemetrexed. The sqNSCLC cohort received Opamtistomig plus paclitaxel and carboplatin Q3W, followed by Opamtistomig maintenance...While follow-up is limited, these results support further evaluation and suggest its novel mechanism could help define a new treatment approach in cancer immunotherapy. Updated results will be presented at WCLC 2026."

Bispecific • Clinical • Metastases • P2 data • Leukopenia • Lung Cancer • Lung Non-Small Cell Squamous Cancer • Lung Non-Squamous Non-Small Cell Cancer • Neutropenia • Non Small Cell Lung Cancer • Solid Tumor

RC148 (ABBV-1480, PD-1/VEGF Bispecific Antibody) Plus Chemotherapy in First-Line Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (IASLC-WCLC 2026) - P1 | "Previous data showed encouraging anti-tumor activity with a manageable safety profile for RC148 monotherapy and combined with docetaxel in patients with NSCLC (ESMO IO Congress, 2025)...Patients with squamous NSCLC (sq-NSCLC) were randomized 1:1 to receive RC148 (10 or 20 mg/kg) plus carboplatin/paclitaxel (Cohort 1), followed by maintenance treatment; patients with non-squamous NSCLC (nsq-NSCLC) were randomized 1:1 to receive RC148 (10 or 20 mg/kg) plus carboplatin/pemetrexed (Cohort 2), also with maintenance...In Cohort 1, RC148 10 mg/kg achieved an ORR of 90.0% (95% CI: 73.5-97.9), with PD-L1-negative (TPS <1%) ORR of 93.3%—exceeding AK112's 71.2% in HARMONi-6...The 10 mg/kg dose, with superior outcomes across histology and high activity irrespective of PD-L1 status, is the recommended phase 3 dose in first-line NSCLC. Pivotal phase 3 studies have been initiated or planned both in China and globally."

Bispecific • Clinical • Metastases • Lung Cancer • Lung Non-Small Cell Squamous Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • PD-L1

Neoadjuvant BNT116 + Cemiplimab + Carboplatin + Paclitaxel in Resectable NSCLC: Preliminary Results From a Phase I Trial (IASLC-WCLC 2026) - P1 | "Surgery was feasible and no impact of neoadjuvant treatment on postsurgical healing was detected. Longer follow-up and additional pathological response data will be presented."

Clinical • IO biomarker • P1 data • Lung Cancer • Neutropenia • Non Small Cell Lung Cancer • Solid Tumor • CLDN6 • MAGEA4 • MAGEC1 • PD-L1 • PRAME

The DUMAS Trial, Neo-Adjuvant Immunotherapy for Pancoast Tumors (IASLC-WCLC 2026) - "Patients received three cycles of neoadjuvant nivolumab (360 mg IV Q3W) plus platinum-doublet chemotherapy (paclitaxel plus carboplatin) prior to surgery. These findings are clinically meaningful and suggest that this approach may improve outcomes in this historically underrepresented population. Updated survival data will be presented at the conference."

Clinical • Immunology • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ALK • EGFR • ROS1

ATHENEA, a Phase II Study of Atezolizumab as Neoadjuvant, Adjuvant and Maintenance Treatment for Stage IIIA-IIIB NSCLC Patients (IASLC-WCLC 2026) - "The standard treatment for unresectable stage III patients is concurrent chemoradiotherapy (cCRT) followed by durvalumab for 1 year (PACIFIC regimen)...Methods : ATHENEA is an ongoing multicenter, open-label, phase II clinical trial (EUCT Number: 2024-515984-68-00) that evaluates the efficacy of 3 cycles of neoadjuvant treatment with atezolizumab 1200 mg plus carboplatin AUC6 and paclitaxel 200mg/m 2 in stage IIIA and IIIB NSCLC patients...Patients will undergo tumor assessments by body CT scan at baseline, at post neoadjuvant treatment prior to surgery or cCRT, after surgery (for resectable patients), after cCRT treatment (for non-resectable patients), during treatment with atezolizumab in adjuvant/post cCRT phase every 12 weeks and thereafter, every 3 months for the first 2 years and every 6 months until the 5-year follow-up period is completed. Currently 47 patients have been included in the study."

Clinical • P2 data • Lung Cancer • Non Small Cell Lung Cancer • Solid Tumor • ALK • EGFR • ROS1 • STK11

FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for taxane-pretreated patients with advanced or metastatic gastroesophageal adenocarcinoma–Final results of the phase III IKFs602/AIO RAMIRIS Study (ESMO 2026) - No abstract available

Clinical • Metastases • P3 data • Gastroesophageal Junction Adenocarcinoma • Oncology • Solid Tumor

KEYNOTE-C93/GOG-3064/ENGOT-en15: Phase 3, Randomized, Open-Label Study of First-Line (1L) Pembrolizumab (Pembro) vs Carboplatin (C) + Paclitaxel (P) in Mismatch Repair-Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (a/rEC) (ESMO 2026) - No abstract available

Clinical • dMMR • Late-breaking abstract • Metastases • Mismatch repair • P3 data • Endometrial Cancer • Oncology • Solid Tumor

A randomized trial of paclitaxel ± tovecimig in previously treated patients with advanced biliary tract cancer (ESMO 2026) - No abstract available

Clinical • Metastases • Biliary Cancer • Biliary Tract Cancer • Oncology • Solid Tumor

Low dose pembrolizumab in addition to neoadjuvant anthracycline and taxane in triple-negative breast cancer: A randomized controlled trial (ESMO 2025) - "Patients with untreated stage II-III TNBC without access to standard dose pembrolizumab (SDPm) were randomized (1:1) to receive neoadjuvant dose-dense chemotherapy (4 cycles of doxorubicin and cyclophosphamide followed by 4 cycles of paclitaxel) with or without 50 mg LDPm administered every 6 weeks for 3 cycles. Conclusions The absolute benefit with LDPm appears numerically comparable to that observed with SDPm in the KN522 trial. Therefore, in resource-constrained settings where SDPm is inaccessible, a low-dose alternative strategy may provide a viable treatment option in patients with TNBC."

Clinical • Late-breaking abstract • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer

Tumor infiltrating lymphocytes (TILs) and pathologic complete response (pCR) in stage II/III HER2+ breast cancer treated with taxane, trastuzumab, and pertuzumab (THP): secondary results from the ECOG-ACRIN EA1181/CompassHER2 pCR trial (SABCS 2025) - P2 | " EA1181 (NCT04266249) enrolled patients (pts) with anatomic clinical stage II/III HER2+ breast cancer who preoperatively received 4 cycles of trastuzumab and pertuzumab with 12 weeks of paclitaxel or docetaxel q3w x 4 (THP), followed by surgery. sTILs were associated with pCR after THP, further supporting the important role of immune mechanisms in HER2+ breast cancer, and highlighting a potentially robust predictive tool to assess pathologic response. Baseline sTILs could potentially inform the preoperative design of future trials of therapy optimalization. Association of baseline sTILs with recurrence free survival in EA1181 will be reported in the future."

Clinical • Tumor-infiltrating lymphocyte • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Triple Negative Breast Cancer • HER-2

Primary Results from the HR+/HER2- Cohort of TBCRC-053 (P-RAD): A Randomized Trial of No, Low, or High Dose Preoperative RADiation with Pembrolizumab and Chemotherapy in Node-Positive, HER2-Negative Breast Cancer (SABCS 2025) - P2 | "Patients subsequently received pembrolizumab with 12 weeks of paclitaxel, followed by 4 cycles of adriamycin-cyclophosphamide (q2wk or q3wk) with pembrolizumab (200 mg q3 wks or 400 mg q6 wks). The addition of 24Gy preop RT to aPD1 significantly increased tumor TCI in HR+/HER2- early-stage BC. Non-irradiated nodal response rates were promising despite over one-third of the study population with grade 1/2 tumors and high disease burden, laying the foundation for a future randomized trial comparing the efficacy of this novel approach against standard of care for node-positive HR+/HER2- BC."

Clinical • IO biomarker • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • CD8 • HER-2 • PGR

Induction Paclitaxel-Cisplatin-Capecitabine for Nasopharyngeal Carcinoma. (PubMed, NEJM Evid) - P3 | "Among patients with high-risk LA-NPC, TPC induction chemotherapy was associated with higher 5-year FFS than PF. (Funded by National Natural Science Foundation of China and State Key Laboratory of Respiratory Disease; ClinicalTrials.gov number, NCT02940925.)."

Clinical • Journal • Epstein-Barr Virus Infections • Nasopharyngeal Carcinoma • Oncology • Respiratory Diseases • Solid Tumor

A Decade of Change: Systemic Treatment Patterns in Clinically Small HER2-Positive Node-Negative Breast Cancer in the Netherlands: A Population-Based Study. (PubMed, Ann Surg Oncol) - "Systemic treatment patterns for cT1N0 HER2-positive breast cancer changed substantially over the past decade, with an increased use of neoadjuvant therapy and especially the Tolaney regimen. Despite these changes, considerable lack of consensus remains, particularly regarding SLNB timing. Further data are needed to guide optimal sequencing of systemic therapy and axillary staging."

Journal • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Experimental evaluation of Nilotinib and Paclitaxel co-delivered via albumin nanoparticles as a therapeutic strategy for lung squamous cell carcinoma. (PubMed, Clin Exp Med) - "This study successfully developed NLB/PTX-NPs, achieving effective co-loading of dual drugs, efficient enrichment, and synergistic delivery at tumor sites. The system demonstrated promising preclinical anti-tumor and anti-metastatic effects in the NCI-H520 models by synergistically inhibiting the NF-κB pathway, thereby providing a novel strategy for the treatment of lung squamous cell carcinoma."

Journal • Non Small Cell Lung Cancer • Oncology • Squamous Cell Carcinoma

Phase 3 study of benmelstobart in combination with chemotherapy followed by sequential combination with anlotinib for the first-line treatment of locally advanced or metastatic squamous non-small cell lung cancer (sq-NSCLC). (ASCO 2025) - P3 | "TQB2450-III-12 is a multicenter, randomized, double-blind, parallel-controlled phase III study of benmelstobart (PD-L1 inhibitor) in combination with chemotherapy followed by sequential combination with anlotinib (multi-targeted angiogenesis inhibitor) versus tislelizumab plus chemotherapy as first-line therapy for locally advanced or metastatic sq-NSCLC...Paclitaxel (175 mg/m2, day 1) and carboplatin (area under the concentration [AUC] of 5, day 1) were given every 3 weeks... Benmelstobart in combination with chemotherapy followed by sequential combination with anlotinib significantly improved PFS, with a manageable safety profile. It might be a new first-line treatment for sq-NSCLC."

Clinical • Combination therapy • IO biomarker • Metastases • P3 data • Lung Cancer • Lung Non-Small Cell Squamous Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (ESCC, RATIONALE 302): Impact on health-related quality of life (HRQoL). (ASCO 2022) - P3 | " Adults with advanced or metastatic ESCC whose disease progressed following prior systemic therapy were randomized 1:1 to either TIS 200 mg IV every 3 weeks or ICC (paclitaxel, docetaxel, or irinotecan). The analysis showed that ESCC pts treated with TIS in the second line had a longer maintenance of HRQoL compared to pts treated with ICC. These results, along with improved survival and favorable safety profile, suggest TIS represents a potential new second-line treatment option for pts with advanced or metastatic ESCC."

Clinical • HEOR • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Fatigue • Gastrointestinal Disorder • Oncology • Pain • Squamous Cell Carcinoma

Tislelizumab Versus Docetaxel in Previously Treated Advanced NSCLC: A Real-World Comparative Study (IASLC-WCLC 2026) - "Within the tislelizumab cohort, adjusted Cox analyses showed that liver metastasis (HR 2.181, p=0.308) and concomitant paclitaxel use (HR 1.992, p=0.303) were associated with a trend toward an increased risk of disease progression, whereas receipt of more than two prior lines of treatment (HR 3.456, p=0.116) and age ≥70 years (HR 2.664, p=0.120) were associated with a trend toward an increased risk of treatment failure. These findings suggest that tislelizumab may not confer superior effectiveness over docetaxel in later-line settings. Poorer ECOG PS was associated with shorter PFS, highlighting the prognostic importance of baseline functional status."

Clinical • Metastases • Real-world • Real-world evidence • Lung Cancer • Non Small Cell Lung Cancer • Solid Tumor

Randomized, global, phase III study of tislelizumab (TIS) + chemotherapy (chemo) vs chemo as first-line (1L) therapy for advanced or metastatic esophageal squamous cell carcinoma (ESCC) (RATIONALE-306): Asia subgroup (ESMO Asia 2022) - P3 | "Methods Adults with unresectable locally advanced or metastatic ESCC, with no prior systemic treatment for advanced disease were enrolled and randomized (1:1; stratified by region, prior definitive therapy, and investigator [INV]-chosen chemo) to receive TIS 200 mg (Arm A) or PBO (Arm B) IV Q3W, with platinum + fluoropyrimidine, or platinum + paclitaxel until disease progression by INV per RECIST v1.1, intolerable toxicity, or withdrawal. Serious TRAEs occurred in 29.9% vs 19.8% of pts, and discontinuation due to treatment-emergent AEs occurred in 28.2% vs 18.1%, in Arm A vs B, respectively. Conclusions In the Asia subgroup, 1L TIS + chemo demonstrated clinically meaningful improvement in OS and improvements in PFS, ORR, and DoR vs PBO + chemo in pts with advanced or metastatic ESCC, with a manageable safety profile, consistent with published results in the overall population."

Clinical • P3 data • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Oncology • Squamous Cell Carcinoma

Ribociclib (RIB) vs. palbociclib (PAL) in patients (pts) with hormone receptor-positive/HER2-negative/HER2-enriched (HR+/HER2-/HER2-E) advanced breast cancer (ABC): A head-to-head phase III study—HARMONIA SOLTI-2101/AFT-58. (ASCO 2023) - P3 | "HER2-E cohort will randomized pts 1:1 to RIB+ET (letrozole or fulvestrant) or PAL+ET. As per recent protocol amendment, BL cohort pts will be treated with paclitaxel plus tislelizumab, an anti PD-1 monoclonal antibody, pts may be offered to try RIB + ET first, and will remain eligible for paclitaxel + tislelizumab upon progression...HARMONIA will recruit in Spain (55 sites), Portugal (5), and US (35) within SOLTI & AFT network. Clinical trial information: NCT05207709."

Clinical • Head-to-Head • Metastases • P3 data • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • HER-2

First-line tislelizumab (TIS) plus chemotherapy (CT) vs placebo (PBO) plus CT in advanced/metastatic esophageal squamous cell carcinoma (ESCC): A post-hoc analysis of different investigator-choice CT and tumor PD-L1 expression level subgroups in RATIONALE-306 (ESMO 2025) - P3 | "Background In the global phase 3 RATIONALE-306 study, random assignment to TIS or PBO was stratified by investigator-choice CT of platinum (cisplatin or oxaliplatin) with 5-FU (fluoropyrimidine or capecitabine) (FP) vs. platinum with paclitaxel (TP), enabling an unbiased analysis of TIS efficacy vs. PBO with these regimens...These findings offer potential insights into selecting CT regimens based on PD-L1 status. Further validation in future studies is needed."

Biomarker • Clinical • IO biomarker • Metastases • Retrospective data • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Oncology • Squamous Cell Carcinoma • PD-L1

A Single-Arm, Open-Label, Prospective Study Evaluating the Safety, Tolerability, and Immunogenicity of the NeoOVSV Vaccine in Patients With Ovarian Cancer After Surgery (clinicaltrials.gov) - P1 | N=9 | Recruiting | Sponsor: West China Hospital | Not yet recruiting ➔ Recruiting

Enrollment open • Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor

Tislelizumab (Tisle) combined with POFI (irinotecan, paclitaxel, oxaliplatin and 5-FU/levoleucovorin) as first-line treatment of advanced gastric/gastroesophageal junction adenocarcinoma (AGC): OS analysis results of the SYLT-023. (ASCO-GI 2025) - P1/2 | "The combination of Tisle + XELOX/FP is a first-line treatment of AGC in China... Tisle+POFI was well tolerated and showed preliminary antitumor activity in AGC. A phase II study is ongoing."

Clinical • Metastases • Esophageal Cancer • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Gastrointestinal Cancer • Oncology • Solid Tumor • HER-2 • PD-L1